Meeting
2016 ASCO Annual Meeting
TACE 2: A randomized placebo-controlled, double-blinded, phase III trial evaluating sorafenib in combination with transarterial chemoembolisation (TACE) in patients with unresectable hepatocellular carcinoma (HCC): Background.
Authors
Tim Meyer
UCL Cancer Institute, University College London, London, United Kingdom
Tim Meyer , Richard Fox , Yuk Ting Ma , Paul J. Ross , Martin James , Richard Strugess , Clive Stubbs , Lucy Wall , Anthony Watkinson , Nigel Hacking , T.R. Jeffry Evans , Peter Collins , Richard Hubner , David Cunningham , John Neil Primrose , Philip James Johnson , Daniel H. Palmer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
ISRCTN93375053
Citation
J Clin Oncol 34, 2016 (suppl; abstr 4018)
DOI
10.1200/JCO.2016.34.15_suppl.4018
Abstract #
4018
Poster Bd #
10
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
A phase III, double-blind, randomized study of nivolumab (NIVO) and ipilimumab (IPI), nivo monotherapy or placebo plus transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC).
First Author: Bruno Sangro
Poster
2016 ASCO Annual Meeting
A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2).
First Author: Andrew X. Zhu
Poster
2016 Gastrointestinal Cancers Symposium
A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2).
First Author: Andrew X. Zhu
Poster
2015 ASCO Annual Meeting
A randomized, double-blind, placebo-controlled phase III study of S-1 in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE).
First Author: Masatoshi Kudo